Clinical Summary
Clinical Summary: A Randomized Controlled Trial of Community-Delivered Heated Hatha Yoga for Moderate-to-Severe Depression
Many patients with major depressive disorder do not respond to, tolerate, or access standard treatments, leaving a need for practical nonpharmacologic options. This trial tests whether community-delivered heated hatha yoga can reduce moderate-to-severe depressive symptoms in a real-world setting, including both medicated and unmedicated patients.
Design
We randomized 80 subjects to 8 weeks of ≥ 2 weekly heated yoga classes (“yoga”) vs a waitlist control (“waitlist”) arm.
N
Eighty participants were randomized; 65 (81%) participants (yoga, n = 33; waitlist, n = 32) were included in the analyses.
Population
individuals with moderate-to-severe symptoms of depression
Duration
8 weeks
Key Findings
- At the week 8 endpoint, yoga participants had significantly lower scores on the IDS-CR than waitlist participants (Cohen d = 1.04, P < .001).
- Depressive symptoms improved faster in the yoga arm than in the waitlist arm (time × arm effect: b = −3.09, P < .001), with overall IDS-CR scores declining over time (time effect: b = −2.61, P < .001).
- In the yoga arm, 59.3% (n = 16) responded to treatment and 44% (n = 12) remitted, compared to 6.3% (n = 2) for both response and remission in the waitlist arm.
- Antidepressant use status did not change the treatment effect on depressive symptoms over time (time × arm × antidepressant use: b = 0.99, P = .31).
- Participants attended 10.3 ± 7.1 classes over the 8-week study period, and 36% (n = 12) attended 12 classes or more; no serious adverse events (SAEs) were reported.
Clinical Bottom Line
Community-delivered heated hatha yoga produced a large antidepressant effect over 8 weeks versus waitlist in adults with moderate-to-severe depression. Benefit was seen despite lower-than-prescribed attendance and without a safety signal for serious adverse events.
Practice Implications
- Consider heated hatha yoga as an adjunctive or stand-alone option for moderate-to-severe depression in patients who are interested in a structured, community-based nonpharmacologic treatment.
- Set expectations that meaningful improvement occurred even though participants attended a mean of 10.3 ± 7.1 classes over 8 weeks, which was below the prescribed ≥ 2 weekly classes.
- Discuss practical barriers up front, because only 36% (n = 12) reached 12 classes or more and participants with higher baseline HDRS-17 scores were less likely to complete follow-up assessments (OR = 0.88 [95% CI = 0.78 to 0.99], P = .04).
- Monitor for mostly mild-to-moderate tolerability issues such as headache, back pain, knee pain, chills/nausea, and dizziness/vertigo, while reassuring patients that no serious adverse events were reported.
